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Abstract
Background: Cytokines and chemokines are key mediators of anti-malarial immunity. We evaluated whether
Intermittent Preventive Treatment in infants with Sulfadoxine-Pyrimethamine (IPTi-SP) had an effect on the
acquisition of these cellular immune responses in Mozambican children. Multiple cytokines and chemokines were
quantified in plasma by luminex, and antigen-specific cytokine production in whole blood was determined by
intracellular cytokine staining and flow cytometry, at ages 5, 9, 12 and 24 months.
Results: IPTi-SP did not significantly affect the proportion of CD3+ cells producing IFN-g, IL-4 or IL-10. Overall, plasma
cytokine or chemokine concentrations did not differ between treatment groups. Th1 and pro-inflammatory responses
were higher than Th2 and anti-inflammatory responses, respectively, and IFN-g:IL-4 ratios were higher for placebo than
for SP recipients. Levels of cytokines and chemokines varied according to age, declining from 5 to 9 months. Plasma
concentrations of IL-10, IL-12 and IL-13 were associated with current infection or prior malaria episodes. Higher
frequencies of IFN-g and IL-10 producing CD3+ cells and elevated IL-10, IFN-g, MCP-1 and IL-13 in plasma were
individually associated with increased malaria incidence, at different time points. When all markers were analyzed
together, only higher IL-17 at 12 months was associated with lower incidence of malaria up to 24 months.
Conclusions: Our work has confirmed that IPTi-SP does not negatively affect the development of cellular immune
response during early childhood. This study has also provided new insights as to how these cytokine responses are
acquired upon age and exposure to P. falciparum, as well as their associations with malaria susceptibility.
Trial Registration: ClinicalTrials.gov: NCT00209795
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Background
In 2009 there were an estimated 68,925,435 cases of
malaria in the African region (78% of worldwide esti-
mates) and 111,885 malaria deaths (91% of worldwide
estimates) [1]. These figures demonstrate that
Plasmodium falciparum malaria remains a major threat
to the health of Africans, in particular children under 5
years of age. In malaria endemic areas, older children
and adults develop immunity to severe morbidity and
death, though remaining susceptible to infection [2,3].
Immunoglobulin passive transfer studies in humans sug-
gest that antibodies are key mediators of naturally
acquired immunity [4]. More recent data [5] suggest
that cellular immunity also plays an important role in
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the protection against P. falciparum disease in humans
[6].
Cytokines and chemokines are considered key media-
tors of anti-malarial immunity. For example, the produc-
tion of cytokines and chemokines by activated
leukocytes, including CD8+ and CD4+ T cells, mediate
mechanisms such as phagocytosis and killing of parasi-
tized erythrocytes [7] and inhibition of parasite growth
and development inside hepatocytes [8].
It has been also shown that cytokines play an impor-
tant role in the immunopathology of malaria and many
field studies have described an association of specific
cytokines with severity of disease, in particular IL-2 [9],
IL-12 [10,11], IFN-g [9,12], IL-1b [13], IL-6 [14,15], TNF
[9,13-22], IL-4 [23-25], IL-10 [9,12,20,26,27], MIP-1b
[28], and TGF-b [29].
There is less field data available on the relevance of
individual cytokines in naturally acquired immunity to
malaria, e.g. IL-12 [30-32], IFN-g [30,32-36], TNF
[30,34,37], or IL-10 [38]. Previous studies have investi-
gated individual or a few cytokines but it is more likely
that a network of cytokine and chemokines determines
protection or susceptibility from P. falciparum infections
[39]. Most studies of cytokine responses have been
cross-sectionals done after the onset of symptoms and
at the initial stages of clinical illness [40-43]. Only a few
studies have assessed longitudinally the evolution of cel-
lular immune responses to infection, and those have
been mostly in adult populations [30,44,45]. Further-
more, while a number of studies have evaluated new-
born cytokine responses in cord blood [46-54], very few
have measured prospectively cellular immune responses
to P. falciparum in infants [55] or children [30,44,56].
In the context of a randomized, placebo-controlled
trial of intermittent preventive treatment in infants with
sulfadoxine-pyrimethamine (IPTi-SP) in Mozambique
[57], we have previously shown that this intervention
had no impact on the antibody responses to P. falci-
parum erythrocytic stage antigens and to variant surface
antigens in Mozambican infants, nor on the capacity of
antibodies to inhibit parasite growth [58,59]. Only a
handful of studies have evaluated the impact of any
malaria control interventions on the development of cel-
lular immune responses. In one study, continuous che-
moprophylaxis for 3 years in Gambian children resulted
in higher lymphoproliferative responses and IFN-g pro-
duction [60], and there was no clinical rebound of
malaria one year after termination of prophylaxis
(despite a decrease in anti-malarial antibody levels). In
another study, permethrin-treated bednets showed a sig-
nificant impact on percent lean body mass in Kenyan
school children, thought to be due to decreased produc-
tion of pro-inflammatory cytokines TNF, IL-1 and IL-6
in this group [61]. However, no study has yet assessed
the impact on the child’s cellular immunity of IPTi-SP,
a safe and efficacious malaria control strategy consisting
in the administration of a full dose of this antimalarial
drug within the Expanded Program on Immunization
(EPI) [62].
In the current study, we have determined prospec-
tively the effect of IPTi-SP on levels of P. falciparum
antigen-specific intracellular cytokines using flow cyto-
metry in children up to 2 years of age. To partially over-
come the difficulty to study this age group because of
limited blood volumes, we used whole blood assays
(WBA) instead of isolated peripheral blood mononuclear
cells for measuring antigen-specific responses by intra-
cellular cytokine staining (ICS). This approach also pro-
vides an environment more similar to that existing in
vivo, and it is faster and more economical [53,63-65]. In
addition, we have used luminex-based microsphere sus-
pension array methods to measure multiple cytokines
and chemokines free in small volumes of plasma [54,66].
Finally, we assessed the factors influencing the levels of
cytokines and chemokines at different time points and
the associations between these and the incidence of
malaria in the first and second years of life. This type of
work has not been as comprehensively conducted in
this age group with a longitudinal design in previous
field studies.
Methods
Study area
The study was conducted at the Centro de Investigação
em Saúde da Manhiça, Manhiça District, southern
Mozambique. This area is characterized by a perennial
malaria transmission mostly due to Plasmodium falci-
parum. Anopheles funestus is the main vector, and the
estimated average number of infective mosquito bites
per person per year was 38 (IDRC and INDEPTH net-
work 2002). For children in this area, SP showed a com-
bined (early and late) therapeutic efficacy rate of 83%,
with an in vivo parasitological sensitivity of 78.6% at day
14 [67].
Study design
The efficacy study was an individually randomized, pla-
cebo-controlled trial [57]. Infants were recruited from
those attending the EPI clinic to receive dose 2 of DTP/
OPV/Hep B between September 2002 and February
2004. Treatment with SP or placebo was administered
at 3, 4, 9 months of age alongside the routine vaccina-
tions. Cross-sectional visits were scheduled at 5, 9, 12
and 24 months of age. For the ancillary immunological
studies within IPTi, we included the last 501 children
recruited in the main trial. At each cross-sectional visit,
capillary blood collected by fingerprick was placed into
EDTA microtainers (1 ml), to obtain plasma for
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extracellular cytokines, and into heparin microtainers
(0.5 ml) for intracellular cytokine determinations. All
immunological assays were performed by personnel who
were blinded to the children’s study group. Clinical sur-
veillance for malaria morbidity was done through pas-
sive case detection. Written informed consent was
obtained from all parents or guardians and ethical
approval for the protocol was obtained from the ethics
review committees of Mozambique and the Hospital
Clinic, Barcelona, Spain. The trial registration number is
NCT00209795 http://clinicaltrials.gov.
For intracellular cytokine staining (ICS) assays, among
those recruited, children with the following criteria were
selected: (i) having received all 3 doses of SP or placebo,
(ii) having a full set of months 5, 9 and 12 blood sam-
ples or the least visits missing, and (iii) having an equal
representation of SP- and placebo-recipients. Among
those, 258 samples were analyzed from month 5, 208
samples from month 9 and 144 samples from month 12.
Once month 24 samples were collected, 143 that had
the previous set were analyzed.
For luminex assays, those children who came for all 4
visits or the least visits missing were prioritized, and
plasmas were selected for analysis when there were suf-
ficient volumes available: 229 children samples from
month 5, 221 from month 9, 225 from month 12, and
158 from month 24.
Multiplex flow cytometric assay to measure cytokines and
chemokines in plasma
Plasma cytokines and chemokines IL-2, IL-12 (p70),
IFN-g, IL-1b, IL-6, TNF, IL-4, IL-5, IL-8, IL-13, IL-10,
IL-7, IL-17, G-CSF, GM-CSF, MCP-1 (MCAF), MIP-1b
were determined using a Bio-plex 100 System (Bio-Rad,
CA, USA) and following manufacturer’s instructions.
According to supplier availability, two types of cytokine
detection kits were used (10-plex and 17-plex). Most
samples (all except those from 26 children) were tested
using the 17-plex kit; the first 27 children (visits 5, 9, 12
months) were tested using the 10-plex kit (which did
not contain IL-1b, IL-5, IL-7, IL-8, IL-12, IL-13 IL-17,
G-CSF, GM-CSF).
Assays were conducted in 96-well Millipore multi-
screen filter plates (Millipore, MA, USA), running in
duplicate 8 standards and 40 plasmas per plate. Plasma
samples previously stored at -80°C were thawed in a
water bath at 37°C, and centrifuged at 1,000 g at 4°C for
10 min. Antigen-coated luminex beads were incubated
with patient plasma, in conjunction with manufacturer’s
reagents. Plasma samples were diluted in Bio-Plex
human sample diluent as 1:3 volumes (30 μl sample +
90 μl diluent). To each sample well, the following were
added in a step wise manner: 50 μl premixed beads
(1×), 50 μl of diluted standard or sample, and 25 μl Bio-
Plex detection antibody (1×), and 50 μl streptavidin-PE
preparation (1×). The mixture was incubated for 30 min
in the dark, at room temperature, on a rotating plat-
form. The wells were then washed 3 times to remove
unbound excess serum using a vacuum filtration system
and a final incubation was done with streptavidin-PE for
10 min at room temperature while shaking at 300 rpm.
Beads were finally resuspended in 125 μl assay buffer,
and shaken on a microplate shaker at 1,100 rpm at
room temperature for 30 sec immediately before reading
the plate on the Luminex 100, in accordance with man-
ufacturer’s instructions. Calibration was done using the
CAL2 high RP1 target value. Concentrations of
unknown cytokines were calculated by plotting
unknowns against a 5-parameter logistic regression stan-
dard curve of 8 points that determine the limits of
detection for each cytokine, expressed as pg/ml. The
coefficient of variation (%CV, reproducibility between
duplicate values) needed to be < 20% to accept the
value for analysis. Results were analyzed using the Bio-
Rad Bioplex Manager Software v4.0.
Intracellular cytokine staining to measure P. falciparum-
specific responses
CD3+ specific intracellular cytokines IFN-g, IL-4 and IL-
10 were measured by ICS. Heparinized whole blood was
aliquoted into two tubes to test in parallel the stimu-
lated and the non-stimulated (negative/background con-
trol) samples. These were respectively incubated with 20
μl extract of P. falciparum schizont lysate at 1 ×
108schizonts/ml or 20 μl uninfected erythrocyte extract,
both in the presence of 1 μg/ml co-stimulatory antibo-
dies to CD28 (clone CD28.2) and CD49d (clone 9F10)
(BD Biosciences, San Jose, CA) for 16 h at 37°C and 5%
CO2. To block cytokine secretion, 1 μM Brefeldin A
(GolgiPlug™, Pharmingen, San Diego, CA) was added
during the final 4 h of incubation. To arrest activation
and avoid loss of activated cells by adhesion to polystyr-
ene tubes, 2 mM EDTA/PBS solution was added for 15
min at room temperature, and tubes were vigorously
vortexed before and after the incubation. In order to
lyse erythocytes and fix lymphocytes, 5 ml 1× FACS
Lysing solution were added. These were vortexed, incu-
bated for 10 min at room temperature, and immediately
placed at -80°C. Frozen samples were thawed in batches
at a later time for parallel processing and staining,
hereby avoiding loss of function or increased back-
ground staining. Thawing was done by briefly placing
samples in a 37°C water bath and immediately washing
off lysing solution using 7 ml Cell Wash buffer. Samples
with clumping/debris of dead cells were previously fil-
tered through 70 μm cell sieve filters (Cell Strainer BD
Falcon), and pellet was resuspended with a pipette in 2
ml permeabilizing solution before vortexing for 10 min
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at RT. Prior to staining, frozen cells were washed with 8
ml wash buffer and centrifuged at 1,500 rpm for 10 min
at room temperature. Supernatant was decanted, resi-
dual pellet was resuspended in 500 μl wash buffer, and
100 μl of each sample were transferred to 96 well round
bottom microtiter plates. Plates were centrifuged at
2,000 rpm for 5 min, then flicked to discard the super-
natants and finally pellets were resuspended by vortex-
ing before adding the staining antibodies. Samples were
stained with a pool of fluorescence-conjugated antibo-
dies: 5 μl CD3 PerCP (clone SK7), 7 μl IFN-g FITC
(clone 25723.11), 3 μl IL-4 PE (clone 8D4-8), and 4 μl
IL-10 APC (clone JES3-19F1) (BD Biosciences, San Jose,
CA). After incubating at room temperature in the dark
for 30 min, samples were washed twice and superna-
tants discarded. Samples were brought up to a total
volume of 300 μl by adding Cell Wash buffer before
acquisition. Stained samples were acquired on a 4-color
FACS Calibur (BD Biosciences) and 50,000-100,000 total
events were collected. Isotype controls were included to
evaluate autofluorescence and to assist in setting the
quadrants. The data were analyzed with CELLQuest
software (BD Biosciences). Lymphocytes were gated
using FSC vs. SSC plots and then SSC vs. CD3+ T cells
plots were used to isolate CD3+ cells (Figure 1). We
analyzed samples in which > 1,000 CD3+ events could
be acquired, and in which defined lymphocyte and CD3
+ cell populations could be identified, thus excluding
those with compromised cell recovery that could con-
found the readings. Each intracellular cytokine was
assessed within its respective fluorescence channel
(PerCP vs. FITC or PE or APC). Non-stimulated control
samples were used to establish the threshold quadrants
of background responses that were applied to quantify
% of positive cytokine-producing cells in paired antigen-
stimulated samples; results were expressed as the per-
centage of cytokine (IL-4, IL-10, IFN-g)-producing CD3
+ cells. Samples were considered positive if there was a
true difference in response proportions (95% confidence
interval [CI]) between the response to test antigens (sti-
mulated) and the background responses to the non-sti-
mulated samples: if the CI was entirely below 0.05%, the
response was negative; if the CI was entirely above
0.05%, the response was positive; if the CI overlapped
with 0.05%, the response was indeterminate.
Definitions and statistical methods
Malaria infection was defined as the presence of asexual
P. falciparum parasites of any density in a blood smear
measured by microscopy and/or by PCR [59]. A clinical
malaria episode was defined as a positive blood smear
plus an axillary temperature of 37.5°C or history of fever
Figure 1 Representative FACS plots showing flow cytometric
detection of P. falciparum antigen-specific IFN-g (FITC-labeled),
IL-4 (PE-labeled) and IL-10 (APC-labeled) following intracellular
cytokine staining of CD3+ lymphocytes. Non-stimulated control
samples (A) were used to establish the threshold quadrants of
background responses that were applied to quantify % of positive
cytokine-producing cells in paired antigen-stimulated samples (B) of
the same child. The UR quadrant represents CD3+ cytokine+
lymphocytes.
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within the prior 24 h. The sensitivity and specificity of
these definitions are 100% and 84%, respectively, in
infants and 100% and 79.4% in children 1-4 years old
[68]. To estimate the incidences, the time at risk was
calculated as the number of person years at risk (PYAR;
episodes per 365.25 days) since the beginning of the
time at risk until the end of follow-up, migration, death
or withdrawn consent, whichever occurred first. Chil-
dren did not contribute to the time at risk or the clinical
malaria cases during the lag periods (an arbitrary lag of
21 days was applied after a case of clinical malaria) to
account for the effective prophylactic time after antima-
larial drug treatment. Months were defined as 30.4 days.
A Shapiro-Wilk normality test revealed a non-normal
distribution of data, therefore all analyses were carried
out in log scale (Ln) to normalise the data, and averages
were expressed as Geometric Means (GM). A Pearson
correlation coefficient was used to measure the degree
of correlation among cytokines. Correlations were con-
sidered “low” if Rho < 0.33, “moderate” if Rho was
between 0.33 and 0.66, or “high” if Rho > 0.66. Ratios
between cytokines were obtained by dividing the values
from each child, transforming that value to its natural
log, then calculating the mean for the total number of
children, and finally transforming that value to its expo-
nential (GM). T-test and chi-square or fisher exact test
were used to compare mean levels or prevalence (tertiles
of distribution) respectively, between IPTi treatment
groups. Unadjusted and adjusted linear regression mod-
els were also used to estimate the effect of IPTi-SP on
the cytokine levels at each visit.
To identify what variables were independently asso-
ciated with cytokine responses (intervention group [SP
or placebo], age at visit, neighborhood of residence, cur-
rent infection and the occurrence of previous clinical
episodes [yes/no]), linear regression models with ran-
dom intercept were estimated, assuming normal distri-
bution of residuals. Selection of the variables for the
final model was done through a stepwise procedure,
where the criterion for including or excluding a variable
was having a p-value ≤ 0.05 or ≥ 0.10 respectively from
the Likelihood ratio test.
To evaluate the relationship between each of the indi-
vidual cytokines at ages 5 and 12 months and the inci-
dence of clinical malaria episodes from 5 to 12 or from
12 to 24 months, respectively, unadjusted and adjusted
negative binomial regression models were estimated
using a stepwise procedure. In the study of multiple epi-
sodes, the probabilities that the criteria to apply Poisson
regressions are met are very low, and the phenomenon
of over dispersion can occur, resulting in underestima-
tion of CI. The negative binomial regression can esti-
mate part of the variance that Poisson regression cannot
identify, and it is exactly the same when there is no over
dispersion. Cytokine responses were treated as continu-
ous values, or categorized by tertiles (cut-offs in Addi-
tional file 1, Table S1). The incidence rate ratio (IRR) of
children with cytokine levels in the highest tertile
against those in the lowest tertile was estimated, as well
as the IRR per 2-fold increase in the value of cytokines.
Co-variates included were: sex, neighborhood of resi-
dence, treatment group and previous malaria episodes.
Two additional separate negative binomial regression
models were estimated including (i) all the cytokine
responses together and (ii) all the cytokine together plus
antibody variables assessed in our previous studies (IgG
against whole parasite and variant antigens on the sur-
face of infected erythrocytes, IgG [total or isotypes] and
IgM against the merozoite antigens AMA-1, EBA-175
and MSP-119) [58,59] to identify what immunological
variables were independently associated with the subse-
quent incidence of clinical malaria.
Data analysis was performed using Stata 11 for Win-
dows (Stata Corporation, College Station, TX). Statistical
significance was defined as a P of < 0.05. Crude P values
reported in the manuscript were interpreted for internal
coherence and consistency of results and biological
plausibility. In addition, P values were adjusted statisti-
cally for multiple comparisons by the Bonferroni correc-
tion (P values not reported). Most of the associations
were no longer statistically significant (P ≥ 0.05) once
adjusted for multiple comparisons, except for a few
associations which remained significant (indicated in the
text and tables).
Results
The clinical and parasitological characteristics of the
children included in this study are reported in Addi-
tional file 2, Table S2.
Intracellular and plasma cytokine responses in relation to
IPTi-SP
The administration of IPTi-SP did not significantly
affect the proportion of CD3+ cells producing intracel-
lular IFN-g, IL-4 or IL-10 in peripheral whole blood
samples stimulated ex-vivo with P. falciparum extract
antigens, at any of the time points, neither by unad-
justed analysis nor by adjusting for previous episodes of
clinical malaria (Table 1).
Also, in general, no significant differences were found
in plasma cytokine or chemokine responses between
treatment groups. There were three isolated exceptions
(IL-12 at 9 months, IL-7 at 12 months, G-CSF at 24
months) in which cases cytokine/chemokine concentra-
tions were consistently higher in children who received
placebo (Table 1), but associations were no longer sta-
tistically significant once adjusted for multiple compari-
sons. The complete raw data depicting levels of each
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Table 1 Comparison of levels of intracellular (P. falciparum-specific) and plasma cytokines and chemokines between
IPTi treatment groups for each cross-sectional visit.
Unadjusted geometric mean Unadjusted linear
regression*
Adjusted linear
regression*,†
Placebo SP P
value‡
P
value
P
value
Cytokines and chemokines Age
(months)
GM 95% CI GM 95% CI Proportional
difference§
Proportional
difference
Intracellular (%
producing
lymphocytes)
IFN-g 5 0.17 0.13 - 0.23 0.13 0.10 - 0.18 0.210 0.77 0.207 0.80 0.293
9 0.05 0.04 - 0.07 0.05 0.04 - 0.07 0.994 1.00 0.994 1.01 0.965
12 0.07 0.05 - 0.11 0.05 0.03 - 0.08 0.348 0.75 0.344 0.76 0.363
24 0.05 0.04 - 0.08 0.04 0.03 - 0.06 0.395 0.80 0.391 0.82 0.433
IL-4 5 0.96 0.81 - 1.12 0.94 0.80 - 1.10 0.864 0.98 0.863 1.00 0.995
9 0.87 0.77 - 0.99 0.82 0.71 - 0.95 0.544 0.94 0.542 0.94 0.546
12 0.80 0.64 - 0.99 0.91 0.71 - 1.17 0.427 1.14 0.422 1.13 0.453
24 0.86 0.70 - 1.04 0.82 0.65 - 1.04 0.814 0.96 0.812 0.97 0.848
IL-10 5 0.37 0.30 - 0.45 0.36 0.31 - 0.43 0.933 0.99 0.933 1.01 0.922
9 0.15 0.12 - 0.19 0.18 0.15 - 0.21 0.285 1.16 0.282 1.15 0.294
12 0.23 0.17 - 0.31 0.22 0.17 - 0.31 0.886 0.97 0.885 0.96 0.852
24 0.32 0.25 - 0.42 0.35 0.27 - 0.45 0.667 1.08 0.664 1.07 0.695
Plasma (pg/ml) IL-2 5 16.17 12.31 - 21.24 17.25 13.04 - 22.82 0.742 1.07 0.741 1.12 0.569
9 12.99 9.48 - 17.79 12.17 9.35 - 15.83 0.752 0.94 0.750 0.93 0.742
12 8.56 6.34 - 11.56 7.17 5.22 - 9.86 0.424 0.84 0.422 0.84 0.438
24 7.09 5.08 - 9.90 5.36 3.83 - 7.49 0.241 0.76 0.237 0.76 0.254
IL-12 5 2.36 1.80 - 3.10 1.87 1.34 - 2.61 0.280 0.79 0.277 0.79 0.284
9 2.37 1.74 - 3.22 1.54 1.21 - 1.96 0.030 0.65 0.030 0.66 0.030
12 1.43 1.14 - 1.78 1.31 1.08 - 1.58 0.550 0.92 0.548 0.93 0.596
24 2.35 1.83 - 3.01 2.22 1.74 - 2.83 0.747 0.95 0.745 0.97 0.844
IFN-g 5 156.50 105.27-232.66 147.8 98.96 - 220.93 0.842 0.94 0.841 0.97 0.928
9 145.93 93.78 - 227.08 115.0 75.84 - 174.44 0.437 0.79 0.435 0.79 0.434
12 77.61 51.44 - 117.10 55.47 35.17 - 87.47 0.280 0.71 0.278 0.71 0.267
24 128.29 85.71 - 192.03 79.89 51.45 - 124.06 0.116 0.62 0.113 0.62 0.106
IL-1b 5 35.03 25.11 - 48.87 41.15 28.66 - 59.09 0.516 1.17 0.514 1.16 0.547
9 11.61 8.50 - 15.86 11.45 8.46 - 15.50 0.950 0.99 0.950 0.99 0.957
12 13.53 9.70 - 18.86 13.98 10.54 - 18.55 0.880 1.03 0.879 1.04 0.869
24 20.05 13.99 - 28.73 17.64 12.12 - 25.69 0.625 0.88 0.622 0.86 0.566
IL-6 5 99.22 72.21 - 136.34 127.6 97.52 - 166.95 0.231 1.29 0.228 1.27 0.254
9 59.24 43.36 - 80.95 56.47 41.93 - 76.05 0.825 0.95 0.824 0.95 0.810
12 76.28 54.51 - 106.75 70.96 51.65 - 97.48 0.756 0.93 0.755 0.93 0.772
24 82.64 55.45 - 123.14 80.68 54.88 - 118.62 0.931 0.98 0.931 0.97 0.907
TNF 5 53.64 38.35 - 75.02 54.50 40.40 - 73.51 0.944 1.02 0.943 1.00 0.991
9 31.91 22.10 - 46.06 27.30 19.11 - 39.00 0.546 0.86 0.544 0.85 0.534
12 21.72 15.16 - 31.12 20.49 14.29 - 29.37 0.820 0.94 0.819 0.95 0.832
24 12.36 7.72 - 19.81 9.86 6.58 - 14.76 0.468 0.80 0.464 0.78 0.430
IL-4 5 3.95 2.83 - 5.52 5.64 4.18 - 7.62 0.117 1.43 0.115 1.49 0.078
9 2.96 1.99 - 4.39 3.64 2.69 - 4.93 0.403 1.23 0.401 1.23 0.406
12 2.49 1.81 - 3.44 2.65 1.93 - 3.64 0.785 1.06 0.783 1.08 0.747
24 1.41 0.98 - 2.04 1.44 1.09 - 1.90 0.939 1.02 0.938 1.01 0.972
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Table 1 Comparison of levels of intracellular (P. falciparum-specific) and plasma cytokines and chemokines between
IPTi treatment groups for each cross-sectional visit. (Continued)
IL-5 5 2.65 2.14 - 3.28 2.66 2.16 - 3.29 0.966 1.01 0.966 1.03 0.833
9 2.57 1.97 - 3.35 2.16 1.73 - 2.69 0.310 0.84 0.307 0.84 0.313
12 2.05 1.68 - 2.50 1.62 1.32 - 2.00 0.109 0.79 0.106 0.80 0.116
24 2.15 1.87 - 2.46 1.97 1.75 - 2.22 0.349 0.92 0.346 0.92 0.351
IL-13 5 0.81 0.66 - 0.99 0.78 0.61 - 0.99 0.811 0.96 0.810 0.97 0.858
9 0.71 0.54 - 0.92 0.57 0.46 - 0.71 0.212 0.81 0.209 0.81 0.213
12 0.56 0.45 - 0.69 0.41 0.32 - 0.52 0.052 0.73 0.050 0.74 0.068
24 1.36 1.11 - 1.67 1.36 1.11 - 1.67 0.993 1.00 0.993 1.01 0.930
IL-10 5 3.77 3.01 - 4.72 4.20 3.32 - 5.32 0.510 1.11 0.508 1.14 0.431
9 3.94 3.00 - 5.16 3.56 2.94 - 4.30 0.540 0.90 0.538 0.89 0.483
12 2.74 2.21 - 3.40 2.45 1.99 - 3.01 0.451 0.89 0.449 0.91 0.536
24 2.53 2.00 - 3.19 2.40 1.80 - 3.20 0.781 0.95 0.779 1.00 0.997
IL-7 5 3.79 3.13 - 4.59 3.37 2.80 - 4.04 0.379 0.89 0.376 0.91 0.465
9 3.98 3.13 - 5.05 3.20 2.71 - 3.79 0.144 0.81 0.142 0.81 0.144
12 3.01 2.55 - 3.54 2.33 1.96 - 2.79 0.038 0.78 0.037 0.78 0.043
24 2.41 2.11 - 2.75 2.29 2.02 - 2.59 0.560 0.95 0.556 0.94 0.519
IL-17 5 4.73 3.47 - 6.45 4.77 3.70 - 6.16 0.968 1.01 0.968 0.99 0.950
9 3.72 2.86 - 4.84 2.87 2.22 - 3.72 0.167 0.77 0.164 0.78 0.169
12 3.01 2.32 - 3.91 2.93 2.29 - 3.76 0.887 0.97 0.886 0.98 0.890
24 5.56 4.37 - 7.08 4.28 3.26 - 5.61 0.152 0.77 0.149 0.76 0.134
G-
CSF
5 17.84 14.28 - 22.29 16.05 12.87 - 20.01 0.502 0.90 0.499 0.91 0.540
9 13.85 10.91 - 17.57 12.32 9.98 - 15.19 0.464 0.89 0.462 0.89 0.467
12 10.48 8.17 - 13.44 11.11 9.18 - 13.44 0.712 1.06 0.710 1.07 0.647
24 27.96 23.58 - 33.16 22.21 19.14 - 25.76 0.044 0.79 0.042 0.79 0.043
GM-
CSF
5 18.29 11.87 - 28.19 19.95 13.03 - 30.54 0.777 1.09 0.776 1.12 0.712
9 18.34 11.82 - 28.46 12.78 8.34 - 19.59 0.243 0.70 0.240 0.70 0.243
12 10.62 7.05 - 16.00 8.10 5.37 - 12.24 0.356 0.76 0.353 0.77 0.363
24 10.91 7.05 - 16.87 8.77 6.23 - 12.35 0.433 0.80 0.429 0.81 0.437
MCP-
1
5 43.17 36.47 - 51.10 46.18 38.41 - 55.51 0.594 1.07 0.592 1.08 0.547
9 41.14 33.21 - 50.95 41.49 35.24 - 48.85 0.949 1.01 0.949 1.01 0.969
12 39.93 33.47 - 47.62 32.71 27.32 - 39.16 0.118 0.82 0.116 0.82 0.122
24 56.52 48.17 - 66.32 50.18 41.82 - 60.22 0.330 0.89 0.326 0.89 0.332
MIP-
1b
5 565.32 474.10 - 674.10 693.5 603.63 - 796.78 0.070 1.23 0.069 1.18 0.131
9 402.91 342.05 - 474.60 456.4 387.36 - 537.80 0.287 1.13 0.285 1.13 0.291
12 487.27 413.65 - 573.99 583.6 482.50 - 705.98 0.157 1.20 0.155 1.20 0.153
24 618.41 515.94 - 741.22 593.8 494.69 - 712.89 0.754 0.96 0.752 0.96 0.770
IL-8 5 200.40 148.28 - 270.82 238.2 183.74 - 308.79 0.389 1.19 0.386 1.15 0.489
9 126.87 99.27 - 162.15 139.2 108.84 - 178.11 0.597 1.10 0.596 1.10 0.592
12 183.34 143.44 - 234.33 228.4 174.16 - 299.56 0.236 1.25 0.234 1.24 0.244
24 208.38 150.71 - 288.13 170.5 123.01 - 236.25 0.386 0.82 0.382 0.81 0.345
The three analyses methods are presented and P values correspond to each one of these.
* Linear regression
† Adjusted by previous episodes of clinical malaria
‡ T test
§ Proportional difference in cytokine/chemokine concentrations in SP-recipients in relation to placebo-recipients
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cytokine and chemokine studied per age and treatment
group is shown in Additional file 3, Figure S1.
Factors associated with individual cytokine responses
Cytokine/chemokine levels varied according to the age
of the child. All of them showed a decline from 5 to 9
months of age. Thereafter, some cytokines continued
decreasing gradually throughout all measurements
(plasma IL-2, TNF, IL-4, IL-10), others reached their
highest levels at 24 months (plasma IL-12, IL-13, IL-17,
MCP-1, G-CSF), and the remaining varied without any
specific pattern (Table 2; Additional file 3, Figure S1).
In addition to age, plasma IL-10 levels were also asso-
ciated with having had previous episodes of clinical
malaria (proportional difference = 1.45 [1.14-1.86], P =
0.0028) and having current infection (proportional dif-
ference = 1.80 [1.41-2.29], P < 0.0001). IL-12 and IL-13
were also associated with having had previous malaria
episodes (proportional difference = 1.35 [1.02-1.77], P =
0.0340; proportional difference = 1.32 [1.04-1.67], P =
0.0234). None of the other factors analyzed in the multi-
variate analyses (gender, neighborhood of residence,
treatment) had any significant association with the cyto-
kines assessed here.
Correlations and ratios between cytokines
We observed no correlation between the magnitude of
IL-4, IL-10 or IFN-g responses measured intracellularly
upon antigen-stimulation and plasma concentrations
(data not shown). A few correlations were found
between plasma cytokines when analyzed against each
other (Additional file 4, Figure S2). Concentrations of
Th1 (IL-2, IL-12, IFN-g) and Th2 (IL-4, IL-5, IL-13)
cytokines correlated moderately within themselves, and
both these two types showed a moderate/high correla-
tion in between them (Th1 vs Th2). Pro-inflammatory
(IL-1b, IL-6, TNF, IL-17) and anti-inflammatory/regula-
tory (IL-10, IL-7) cytokines correlated moderately within
themselves, and both these showed a moderate/low cor-
relation between them (pro- vs anti-inflammatory). Che-
mokines G-CSF and GM-CSF both correlated
moderately/highly to Th1 and Th2 type cytokines,
whereas MCP-1 correlated with most anti-inflammatory
cytokines and MIP-1 b and IL-8 correlated with most
pro-inflammatory cytokines.
We examined whether there was a transition from
Th2 to Th1 [55] or from anti-inflammatory to pro-
inflammatory cytokines with age in early infancy by ana-
lyzing the ratios. Overall, Th1 responses were higher
than Th2 responses over the 2 years of life (Additional
file 3, Figure S1), and the ratio of IFN-g:IL-4 increased
from 5 to 24 months (Table 3). When data was stratified
by treatment, IFN-g:IL-4 ratios were higher for placebo
than for SP recipients at all ages (Table 3), particularly
at age 24 months coinciding with the highest prevalence
of P. falciparum infection (7.7% at 5 months, 13.5% at 9
months, 8% at 12 months and 26.6% at 24 months).
Overall, the pro-inflammatory responses were higher
than anti-inflammatory responses over the 2 years of life
(Additional file 3, Figure S1), and the ratio of TNF:IL-10
decreased from 5 to 24 months (Table 3).
Individual cytokines and incidence of malaria
Elevated cytokine responses, both antigen-specific and
non-specific, were not associated with a reduction in the
subsequent incidence of clinical malaria in unadjusted
or adjusted analyses (Table 4). In some cases there was
an association between higher cytokine levels and higher
malaria incidence and this was manifested at certain age
intervals (5-12 months or 12-24 months). In particular,
intracellular IFN-g and IL-10 production by CD3+ cells
was associated with higher incidence of malaria during
the first year of age but not in the second year (Table
4). Adjusting for previous episodes did not affect these
results. After Bonferroni correction for multiple compar-
isons, a non significant trend association was still
observed (Table 4).
Associations between individual plasma cytokines and
incidence of malaria were observed throughout the two
years, but mostly in the second year. High concentra-
tions of IL-10 and MCP-1 in plasma were associated
with higher malaria incidence in both time intervals and
by all analysis methods (Table 4). High IL-13 was also
positively associated with incidence of malaria as ana-
lysed by all methods but only during the second year. A
few disperse significant associations for plasma IFN-g,
IL-1b, IL-4, IL-5, IL-7, G-CSF and GM-CSF were also
observed during the second year, when adjusted the
analyses by the variables included in the multivariate
model; all were in the same direction of higher concen-
trations correlating with increased malaria risk (Table
4). After correction for multiple comparisons, some sta-
tistically significant associations remained for MCP-1,
IFN-g, IL-10 and IL-5 (Table 4).
Multiple cytokines and incidence of malaria
We did a multiple regression analysis in which we used
a stepwise procedure to determine the variables that
were independently associated with incidence of malaria.
All cytokines were included in the list of variables taken
into account for the stepwise procedure. Significant
associations were only observed between higher levels of
intracellular IFN-g at 5 months and higher malaria inci-
dence in the follow up interval 5-12 months (IRR 1.28,
95% CI 1.03-1.58, P = 0.0234). Similarly, higher concen-
trations of plasma IFN-g (IRR 1.15, 95% CI 1.05-1.27, P
= 0.0040) and MCP-1 (IRR 1.60, 95% CI 1.22-2.10, P =
0.0007) at 12 months were associated with higher
Quelhas et al. BMC Immunology 2012, 13:5
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Table 2 Intracellular and plasma cytokines and chemokines by age, analyzed by multivariate random-effect models
estimated by stepwise procedure and adjusted by previous episodes, current infection, IPTi treatment, gender and
neighborhood of residence.
Cytokines and chemokines Age (months) Proportional difference 95% CI P value* Overall P value
Intracellular IFN-g 5 1 - - < 0.0001
9 0.36 0.26; 0.48 < 0.0001
12 0.41 0.29; 0.57 < 0.0001
24 0.32 0.23; 0.45 < 0.0001
IL-10 5 1 - - < 0.0001
9 0.45 0.37; 0.55 < 0.0001
12 0.63 0.50; 0.78 < 0.0001
24 0.92 0.74; 1.15 0.4700
Plasma IL-2 5 1 - - < 0.0001
9 0.74 0.58; 0.95 0.0193
12 0.47 0.37; 0.60 < 0.0001
24 0.38 0.29; 0.51 < 0.0001
IL-12 5 1 - - 0.0001
9 0.87 0.69; 1.10 0.2428
12 0.63 0.50; 0.79 0.0001
24 1.02 0.79; 1.31 0.9070
IFN-g 5 1 - - < 0.0001
9 0.84 0.59; 1.21 0.3510
12 0.43 0.30; 0.61 < 0.0001
24 0.69 0.47; 1.03 0.0703
IL-1b 5 1 - - < 0.0001
9 0.30 0.22; 0.40 < 0.0001
12 0.36 0.27; 0.48 < 0.0001
24 0.51 0.38; 0.70 < 0.0001
IL-6 5 1 - - 0.0001
9 0.51 0.38; 0.68 < 0.0001
12 0.65 0.49; 0.87 0.0032
24 0.75 0.55; 1.03 0.0806
TNF 5 1 - - < 0.0001
9 0.54 0.39; 0.73 0.0001
12 0.39 0.29; 0.53 < 0.0001
24 0.21 0.15; 0.30 < 0.0001
IL-4 5 1 - - < 0.0001
9 0.69 0.53; 0.90 0.0073
12 0.54 0.41; 0.71 < 0.0001
24 0.31 0.23; 0.41 < 0.0001
IL-5 5 1 - - 0.0001
9 0.88 0.75; 1.04 0.1450
12 0.68 0.58; 0.81 < 0.0001
24 0.77 0.65; 0.93 0.0056
IL-13 5 1 - - < 0.0001
9 0.77 0.64; 0.92 0.0045
12 0.58 0.49; 0.70 < 0.0001
24 1.59 1.30; 1.94 < 0.0001
IL-10 5 1 - - < 0.0001
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malaria risk during the 12-24 month period. In contrast,
in this analysis higher plasma concentrations of IL-17 at
12 months were associated with lower malaria incidence
during the interval 12-24 months (IRR 0.80, 95% CI
0.69-0.93, P = 0.0035). Other co-variates that were sig-
nificantly associated with malaria incidence, indepen-
dently of the cytokine concentrations, were having had a
previous episode in the second year of life (IRR 4.63,
95% CI 2.59-8.26, P < 0.0001), and the child’s neighbor-
hood of residence in both time intervals (P < 0.0001).
When antibody variables from prior studies were also
included in the stepwise model together with all cyto-
kines and co-variates, significant associations were only
observed for higher intracellular IFN-g at 5 months and
higher malaria incidence during the follow up interval
5-12 months (IRR 1.26, 95% CI 1.01-1.57, P = 0.0381).
At 12 months, higher plasma IFN-g (IRR 1.26, 95% CI
1.11-1.44, P = 0.0004) and IL-5 (IRR 1.27, 95% CI 1.04-
1.55, P = 0.0203) correlated with higher incidence of
malaria up to 24 months, while higher IL-17 plasma
concentrations were associated with lower malaria risk
during the 12-24 month period (IRR 0.84, 95% CI 0.71-
0.98, P = 0.0300). Likewise, the additional variables that
independently showed significant associations with
malaria risk were having had a previous episode in the
second year of life (IRR 3.16, 95% CI 1.64-6.09, P <
Table 2 Intracellular and plasma cytokines and chemokines by age, analyzed by multivariate random-effect models
estimated by stepwise procedure and adjusted by previous episodes, current infection, IPTi treatment, gender and
neighborhood of residence. (Continued)
9 0.85 0.71; 1.03 0.0941
12 0.60 0.50; 0.73 < 0.0001
24 0.53 0.43; 0.66 < 0.0001
IL-7 5 1 - - < 0.0001
9 0.99 0.86; 1.15 0.9244
12 0.74 0.64; 0.86 < 0.0001
24 0.66 0.56; 0.77 < 0.0001
IL-17 5 1 - - < 0.0001
9 0.68 0.54; 0.85 0.0009
12 0.63 0.50; 0.79 0.0001
24 1.05 0.82; 1.35 0.6774
G-CSF 5 1 - - < 0.0001
9 0.77 0.64; 0.91 0.0032
12 0.64 0.53; 0.76 < 0.0001
24 1.50 1.24; 1.81 < 0.0001
GM-CSF 5 1 - - < 0.0001
9 0.78 0.56; 1.09 0.1525
12 0.49 0.35; 0.68 < 0.0001
24 0.52 0.36; 0.75 0.0004
MCP-1 5 1 - - < 0.0001
9 0.92 0.80; 1.06 0.2724
12 0.80 0.70; 0.93 0.0025
24 1.22 1.04; 1.42 0.0156
MIP-1b 5 1 - - < 0.0001
9 0.68 0.58; 0.80 < 0.0001
12 0.85 0.73; 1.00 0.0437
24 0.98 0.82; 1.16 0.7803
IL-8 5 1 - - 0.0003
9 0.60 0.47; 0.77 0.0001
12 0.94 0.73; 1.20 0.6171
24 0.89 0.68; 1.17 0.3991
Intracellular IL-4 is not included (null model). The first P value corresponds to the comparison in between ages and the second corresponds to the overall
comparison.
* Each age in relation to 5 months
Quelhas et al. BMC Immunology 2012, 13:5
http://www.biomedcentral.com/1471-2172/13/5
Page 10 of 18
0.0006), and the neighborhood in both time intervals (P
< 0.0001).
Finally, no significant differences in cytokine or chemo-
kine levels were found in relation to parasite density (data
not shown). Levels of cytokines or chemokines could not
be analysed in relation to incidence of severe malaria due
to its low incidence (Additional file 2, Table S2).
Discussion
In the context of a clinical trial evaluating the safety and
efficacy of IPTi-SP as a malaria control tool during
infancy, we studied prospectively the cytokine responses
to P. falciparum antigens and the concentrations of
plasma cytokines and chemokines at multiple time
points during a 2 year follow up period. The longitudi-
nal design and the established demographic and morbid-
ity surveillance systems allowed for a rigorous and
complete documentation of clinical malaria cases that
could provide insights into the acquisition of cytokine/
chemokine responses in children living in a malaria
endemic area, how they are influenced by age and P. fal-
ciparum exposure, and the correlation between these
responses and incidence of symptomatic malaria.
One of the main findings of this study was that overall
there were no differences in the magnitude of intracellu-
lar or plasma cytokines/chemokines between IPTi treat-
ment groups, except for some plasma cytokines and
chemokines in which children receiving placebo had
higher concentrations than those receiving SP (IL-12 at
9 months, IL-7 at 12 months and G-CSF at 24 months).
In these cases, we hypotesize that placebo recipients,
who suffered more P. falciparum infections than SP
recipients owing to the efficacy of IPTi [57] had more
systemic immune activation and higher levels of some
plasma cytokines. However, of these, only IL-12 was
directly associated to previous episodes of malaria in the
multivariate analysis; to our knowledge, there is no data
in the literature on the influence of P. falciparum infec-
tion or malaria interventions in the concentrations of
IL-7 or G-CSF in peripheral blood. The levels of these
cytokines/chemokines at those time points were not
clearly associated with subsequent incidence of malaria.
Among the factors that significantly affected the levels
of cytokines (both intracellular and plasma), age was the
most prominent. Without exception, all cytokines varied
significantly in magnitude from the first visit to at least
one of the following visits. In all cases, there was a
decrease of cytokine values from 5 to 9 months, and
some had the highest levels at 24 months. This fluctua-
tion is not surprising as cross-sectional samplings were
not scheduled to pick up bursts of production upon
infection and most plasma cytokines’ half-lives are short
[34], thus may not represent a long lasting response. In
addition, cytokine production is stimulated and regu-
lated by many different factors within the cellular
responses network, and while some are specific to infec-
tion, other are innate or are produced in response to
acute or systemic inflammatory conditions.
In contrast to antibody responses that are strongly
affected by past or present malaria infection [59], para-
site exposure appeared to have a minor effect on the
concentrations of cytokines. Plasma IL-10 increased sig-
nificantly in children with previous episodes or current
infection, and higher levels of IL-12 and IL-13 were also
associated with previous episodes. Each of these cyto-
kines belongs to a different family (immuno-regulatory,
Th1 and Th2 respectively) therefore it seems that the
limited effect of exposure to P. falciparum infection was
generalized and not biased towards a specific type. Simi-
lar observations have been reported [9] where malaria
patients responded to P. falciparum infected erythro-
cytes with significant increases in the percentage of IL-
2, IFN-g, and TNF, but also IL-10, positive cells.
We analyzed the correlations and ratios among some
representative cytokine families, as they have synergistic
and antagonistic effects on each other to regulate the
immune system. First, we observed no correlation
between intracellular and plasma IL-4, IL-10 or IFN-g,
which is not uncommon as they represent two different
measurements. Intracellular cytokines were produced by
CD3+ cells after antigen stimulation in vitro (recall
response) whereas plasma cytokines reflect what is pre-
sent ex-vivo in peripheral blood (non malaria specific),
and may be produced by many types of cells. In another
Table 3 Ratios between prototype Th1:Th2 and pro-: anti-inflammatory cytokines.
5 months 9 months 12 months 24 months
Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI
Overall 32 31.73 - 32.27 39 38.73 - 39.27 25 24.69 - 25.31 71 70.75 - 71.25
IFN-g:IL-4 SP 26 25.64 - 26.36 32 31.62 - 32.38 21 20.61 - 21.39 56 55.62 - 56.38
Placebo 40 39.62 - 40.38 49 48.62 - 49.38 31 30.54 - 31.46 91 90.68 - 91.32
Overall 14 13.80 - 14.20 8 7.79 - 8.21 8 7.78 - 8.22 4 3.69 - 4.31
TNF:IL-10 SP 13 12.71 - 13.29 8 7.73 - 8.27 8 7.70 - 8.30 4 3.58 - 4.42
Placebo 14 13.73 - 14.27 8 7.69 - 8.31 8 7.67 - 8.33 5 4.55 - 5.45
Quelhas et al. BMC Immunology 2012, 13:5
http://www.biomedcentral.com/1471-2172/13/5
Page 11 of 18
Table 4 Intracellular and plasma cytokines and chemokines and their association with incidence of malaria during the first and second years of age.
5 - 12 months 12 - 24 months
Tertiles* Two-fold increment† Tertiles Two-fold increment
Unadjusted Adjusted‡ Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Cytokines and
chemokines
IRR 95%
CI
P
value§
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IRR 95%
CI
P
value
IFN-g 3.24 1.13 -
9.33
0.052 4.62 1.58 -
13.47
0.004 1.21 1.03 -
1.43
0.021 1.26 1.07 -
1.49
0.003 0.95 0.38 -
2.39
0.635 0.68 0.32 -
1.45
0.533 0.97 0.84 -
1.11
0.639 0.96 0.85 -
1.08
0.5226
Intracellular IL-4 1.49 0.64 -
3.48
0.645 1.31 0.62 -
2.77
0.783 1.19 0.90 -
1.58
0.212 1.17 0.91 -
1.49
0.213 0.53 0.20 -
1.37
0.404 0.78 0.35 -
1.72
0.816 0.81 0.60 -
1.10
0.178 0.95 0.75 -
1.20
0.6635
IL-10 3.11 1.12 -
8.67
0.086 3.40 1.30 -
8.89
0.033 1.32 1.04 -
1.67
0.022 1.38 1.11 -
1.71
0.004 0.97 0.38 -
2.47
0.989 1.39 0.68 -
2.82
0.239 0.98 0.80 -
1.20
0.833 0.96 0.82 -
1.12
0.5904
IL-2 2.71 0.94 -
7.83
0.131 2.13 0.83 -
5.42
0.219 1.19 0.97 -
1.45
0.083 1.11 0.95 -
1.29
0.200 1.54 0.66 -
3.59
0.423 1.98 1.01 -
3.90
0.055 1.12 0.98 -
1.29
0.090 1.11 1.00 -
1.24
0.051
IL-12 1.38 0.56 -
3.41
0.309 1.53 0.71 -
3.30
0.080 1.10 0.91 -
1.34
0.330 1.06 0.90 -
1.25
0.453 1.63 0.63 -
4.21
0.528 1.87 0.91 -
3.82
0.223 1.09 0.88 -
1.35
0.422 1.10 0.92 -
1.32
0.266
IFN-g 0.92 0.37 -
2.32
0.929 0.99 0.44 -
2.21
0.378 1.00 0.89 -
1.13
0.992 0.98 0.89 -
1.08
0.706 1.28 0.56 -
2.93
0.836 3.60 1.79 -
7.23
0.001 1.05 0.95 -
1.16
0.316 1.16 1.07 -
1.26
0.0004
IL-1b 1.42 0.43 -
4.73
0.654 1.24 0.41 -
3.71
0.653 1.00 0.84 -
1.19
0.975 1.02 0.87 -
1.20
0.813 1.52 0.63 -
3.68
0.050 2.11 1.11 -
4.01
0.009 1.11 0.94 -
1.31
0.194 1.18 1.04 -
1.33
0.011
IL-6 1.03 0.40 -
2.69
0.967 1.05 0.45 -
2.45
0.967 1.00 0.85 -
1.18
0.979 1.02 0.88 -
1.19
0.747 1.52 0.67 -
3.46
0.609 1.86 0.95 -
3.63
0.184 1.10 0.95 -
1.26
0.194 1.16 1.03 -
1.30
0.013
Plasma TNF 1.53 0.52 -
4.48
0.716 2.08 0.80 -
5.43
0.116 1.13 0.95 -
1.34
0.166 1.12 0.97 -
1.30
0.117 1.00 0.43 -
2.33
0.926 1.37 0.68 -
2.77
0.580 1.05 0.94 -
1.19
0.390 1.06 0.96 -
1.16
0.243
IL-4 1.28 0.48 -
3.41
0.506 1.21 0.53 -
2.78
0.516 1.08 0.94 -
1.24
0.253 1.07 0.95 -
1.20
0.271 1.83 0.82 -
4.07
0.168 2.26 1.19 -
4.27
0.041 1.11 0.98 -
1.25
0.093 1.16 1.05 -
1.29
0.004
IL-5 1.67 0.58 -
4.80
0.618 1.74 0.69 -
4.37
0.485 1.13 0.87 -
1.48
0.347 1.05 0.84 -
1.32
0.652 1.90 0.77 -
4.69
0.329 2.80 1.43 -
5.49
0.001 1.15 0.89 -
1.49
0.289 1.39 1.13 -
1.70
0.002
IL-13 1.35 0.46 -
3.92
0.527 1.70 0.66 -
4.37
0.114 1.22 0.92 -
1.62
0.157 1.19 0.94 -
1.50
0.132 3.33 1.21 -
9.15
0.038 3.26 1.45 -
7.32
0.016 1.42 1.11 -
1.81
0.005 1.32 1.07 -
1.62
0.006
IL-10 3.36 1.27 -
8.87
0.035 3.06 1.21 -
7.76
0.025 1.28 1.04 -
1.57
0.016 1.17 0.99 -
1.38
0.059 3.61 1.60 -
8.13
0.009 2.30 1.19 -
4.44
0.045 1.43 1.16 -
1.75
0.0004 1.25 1.06 -
1.47
0.006
IL-7 1.77 0.62 -
5.04
0.529 1.41 0.56 -
3.52
0.594 1.26 0.92 -
1.73
0.137 1.10 0.85 -
1.43
0.456 1.56 0.62 -
3.96
0.242 2.16 1.09 -
4.30
0.029 1.20 0.88 -
1.65
0.245 1.34 1.04 -
1.72
0.019
IL-17 0.67 0.25 -
1.83
0.622 0.76 0.33 -
1.74
0.551 1.01 0.83 -
1.23
0.914 1.04 0.88 -
1.22
0.681 0.78 0.30 -
2.00
0.055 0.80 0.36 -
1.77
0.278 0.97 0.79 -
1.20
0.785 0.92 0.78 -
1.09
0.342
G-
CSF
1.83 0.64 -
5.27
0.439 2.42 0.95 -
6.20
0.074 1.25 0.95 -
1.64
0.102 1.21 0.96 -
1.53
0.085 2.41 0.90 -
6.46
0.207 3.10 1.46 -
6.56
0.013 1.25 1.00 -
1.55
0.048 1.35 1.13 -
1.63
0.001
GM-
CSF
1.19 0.41 -
3.42
0.945 1.19 0.48 -
2.97
0.490 1.05 0.92 -
1.21
0.475 1.04 0.93 -
1.16
0.517 1.63 0.64 -
4.10
0.187 2.41 1.16 -
5.05
0.011 1.11 0.99 -
1.26
0.077 1.13 1.03 -
1.24
0.010
MCP-
1
3.01 1.18 -
7.63
0.064 3.16 1.37 -
7.25
0.015 1.64 1.21 -
2.23
0.001 1.66 1.29 -
2.15
<
0.001
3.07 1.34 -
7.06
0.008 2.85 1.43 -
5.69
0.007 1.31 1.02 -
1.69
0.038 1.36 1.11 -
1.67
0.003
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Table 4 Intracellular and plasma cytokines and chemokines and their association with incidence of malaria during the first and second years of age.
(Continued)
MIP-
1b
0.52 0.20 -
1.35
0.113 0.83 0.34 -
2.07
0.341 0.92 0.67 -
1.27
0.620 1.10 0.80 -
1.51
0.571 1.50 0.67 -
3.40
0.396 0.98 0.50 -
1.94
0.329 0.98 0.78 -
1.24
0.859 0.93 0.76 -
1.13
0.430
IL-8 0.68 0.27 -
1.71
0.646 0.77 0.34 -
1.73
0.809 0.95 0.79 -
1.14
0.580 0.98 0.82 -
1.16
0.781 0.72 0.32 -
1.62
0.402 0.61 0.30 -
1.22
0.100 0.95 0.80 -
1.12
0.543 0.97 0.84 -
1.11
0.633
For each time interval (5 to 12 months and 12 to 24 months) P values correspond to each one of the analyses methods used.
* Incidence rate ratio in high tertile relative to low tertile
† Incidence rate ratio in two-fold increment
‡ Adjusted by treatment group, gender, previous episodes of clinical malaria, current infection, neighborhood
§ Negative binomial regression model using likelihood ratio test. In bold, P values that remained statistically significant (P < 0.05) or border line significant (P < 0.095) after Bonferroni correction for multiple
comparisons. Corrected P values (in order from top to bottom, left to right): intracellular IFN-g, 0.083, 0.052; intracellular IL-10, 0.076; plasma IFN-g, 0.022, 0.008; plasma IL4, 0.077; IL-5, 0.027, 0.031; IL-13, 0.093;
plasma IL-10, 0.008; G-CSF, 0.018; MCP-1, 0.019, 0.002, 0.053.
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study [66], the strength of associations between serum
and cellular cytokines varied greatly, suggesting that
serum cytokines at best only weakly reflect peripheral
blood cell cytokine production and balances. We
observed a high ratio between prototype Th1 (IFN-g)
and Th2 (IL-4) cytokines at all ages, and this proportion
increased when looking only at the placebo group possi-
bly indicating more parasite exposure. We also observed
the relative transition from Th2 to Th1 responses with
age [69].
We also assessed whether cytokines and chemokines
were associated with subsequent incidence of malaria,
and what factors affected these associations. Overall,
high cytokine responses were not associated with a
reduced incidence of clinical malaria when analyzed
individually. Only when all cytokines where analyzed
together in relation to risk of malaria, a significant asso-
ciation towards a decreased risk was found for IL-17 in
the second year of life. IL-17 is a Th17 cytokine and its
relation to various infectious agents has been described
[70]. However to our knowledge, there has not been any
study reporting a role for IL- 17 in protection against
human malaria.
In fact, the most common finding was that there were
no associations, or that higher levels of some cytokines
correlated with increased malaria incidence. In particu-
lar, IL-10 (intracellular and plasma) and MCP-1 were
more consistently associated with incidence of malaria,
and this association was not explained by age or pre-
vious episodes. IL-10, an immunoregulatory cytokine, is
extensively reported in relation to malaria immuno-
pathogenesis [9,12,20,26,27] and not so much associated
with immunity [38]. Higher IL-10 has been associated
with less effective parasite clearance [71]. To our knowl-
edge nothing has been reported for chemokine MCP-1
in children in relation to immunity, and it does not cor-
relate with any of the other cytokines associated with
increased incidence of malaria. In pregnant women,
MCP-1 concentrations were higher in the placentas of
primiparous women (more susceptible to malaria) than
in those of multiparous women [46].
In addition, IFN-g (intracellular and plasma) and IL-13
were also associated with malaria incidence, but these
were dependent on age and/or previous episodes. A few
other disperse associations were observed during the
second year for plasma IL-1b, IL-4, IL-5, IL-7, G-CSF,
GM-CSF, when adjusted by previous episodes. These
results suggest that the responses measured were not
necessarily part of an acquired protective response, but
rather could be interpreted as biomarkers of physio-
pathological processes. In other studies, IL-13, IL-4 and
IL-5, Th2-type cytokines, have been associated with
reduced parasite killing [24]. Production of IL- 4 but
not IFN-g by activated human T cells has been
associated with elevated antibodies to malaria antigens
[72], and consistent with this, our previous studies also
found correlations between higher antibody levels and
increased malaria risk (Dobaño et al. in press).
Responses associated with reduced malaria incidence
would more likely be expected in the antigen-specific
cytokines, as measured by ICS. Blood cells from donors
in malaria endemic areas stimulated with Plasmodium
antigens are known to activate many types of cells, with
production of both IFN-g (Th1 type) and IL-4 (Th2
type) [72]. IFN-g is thought to be a central mediator of
protective immune responses against blood stages of
malaria [73]. Surprisingly, in our study, increased fre-
quency of IFN-g positive CD3+ cells at 5 months was
associated with higher incidence of malaria up to 1 year.
This is in contrast with other studies since IFN-g is
more often reported to confer protection [30,32-36]
than pathology [9,12,74]. In most of these studies IFN-g
was measured in older children or adults and it is likely
that the immature immune system of the infant
responds differently. In the second year, however, there
were no significant associations between intracellular
cytokines and incidence of malaria. At a population
level, memory-like IFN-g responses have been measured
following malaria infection [75] and it has been reported
that IFN-g responses are both more prevalent and of
greater magnitude at the end of the rainy malaria trans-
mission season [45], thus showing that IFN-g might also
be a marker of exposure.
The apparent predisposition of children with higher
cytokine responses to increased malaria risk might also
be influenced by genetic factors. Many studies have
shown associations between genetic polymorphisms,
immunoregulation, phenotypes and disease risk [76-91],
but unfortunately this was not assessed in this study.
Other factors not evaluated that could help explain
these associations would be malnutrition [92,93], co-
infection with HIV or other pathogens [94], or prenatal
exposure [95]. The duration and/or the nature of anti-
gen exposure in utero appears to govern the outcome
with respect to neonatal immune responses, such that
placental malaria induce antigen-specific IL-10-produ-
cing regulatory T cells that can inhibit Th1-type
responses, while antigen-specific IFN-g production pre-
dominate in babies born to mothers successfully treated
for malaria during gestation [95]. Prenatal infection
could thus contribute to the P. falciparum-specific IFN-
g and IL-10 response pattern in 5-month old children
seen in this study.
Conclusions
Our work has further confirmed that IPTi-SP is a safe
intervention that does not compromise the development
of a wide range of cytokines and chemokines thought to
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be major contributors to anti-malarial immunity in
infancy. This study has also given some insights as to
how these responses are acquired upon age and expo-
sure to the P. falciparum parasite. Due to the multiple
comparisons performed, isolated findings are interpreted
with caution, and only those associations that showed
consistency and biological plausibility are considered
here as potential true findings. Despite the low and het-
erogeneous antigen-specific cytokine responses observed,
infant field studies such as the current one help to
advance the understanding of the relationship between
innate and adaptive cellular immune responses. Even-
tually, an effective orchestration of both types of
immune responses is necessary for the generation of an
efficient and non-pathogenic resolution of the malarial
disease.
Additional material
Additional file 1: Table S1. Definition of the distribution of tertiles
for cytokine production: low tertile (minimum to tertile cut-off 1),
medium tertile (tertile cut-off 1 to tertile cut-off 2), and high tertile
(tertile cut-off 2 to maximum).
Additional file 2: Table S2. Description of the clinical and
parasitological characteristics of the groups of children receiving
IPTi with SP or placebo in whom cytokine and chemokine
responses were evaluated. This description includes episodes of clinical
malaria between 5 and 12 months of age, and between 12 and 24
months of age, which constituted the two follow up periods defined in
the immunology study ancillary within the IPTi clinical trial conducted in
Manhiça.
Additional file 3: Figure S1. Intracellular and plasma cytokines and
chemokines in Mozambican infants receiving IPTi with SP (right) or
placebo (left), at 5, 9 12 and 24 months. Cytokine values (Y axis)
are expressed as % producing lymphocytes for intracellular
cytokines, and as pg/ml for plasma cytokines/chemokines. In the
weighted scatter plots the area of the symbol is proportional to the
number of observations. Geometric mean and 95% confidence intervals
are indicated by horizontal continuous and discontinuous lines
respectively.
Additional file 4: Figure S2. A) Correlation among cytokines, B)
Correlation coefficients and strength of correlation.
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